Skip to content

house · Committee report

H. Rept. 119-722

DEONDRA DIXON INCLUDE PROJECT ACT OF 2025

2026-07-02

Committees

Associated legislation

Text

Purpose and Summary

H.R. 3491, introduced on May 19, 2025, by Representatives Diana DeGette (D-CO) and Richard Hudson (R-NC), would authorize the INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project at the NIH, which promotes the scientific understanding of Down syndrome and co-occurring conditions and improve the quality of life of individuals with Down syndrome and their families. This bill would also require reporting to Congress on the program's progress and related research.

Background and Need for Legislation

The INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) Project was established in June 2018 at the direction of Congress to conduct research on critical health and quality-of-life needs for individuals with Down syndrome. The project investigates conditions that affect individuals with Down syndrome and the general population, such as Alzheimer's disease and dementia, autism, cataracts, celiac disease, congenital heart disease, and diabetes.\1\ Individuals with Down syndrome have an increased risk of various medical conditions, including, but not limited to, congenital cardiac issues, autoimmune conditions, and Alzheimer's disease.\2\ The life expectancy for individuals with Down syndrome has increased from roughly 25 years old in 1983 to roughly 60 years old today.\3\ Approximately half of people with Down syndrome will develop dementia due to Alzheimer's disease; by 40 years old, the majority of people with Down syndrome are at a heightened risk for developing Alzheimer's disease.\4\ Additionally, across their lifespan, individuals with Down syndrome typically have multiple co-occurring conditions.\5\ Further research would help improve the quality of life for people with Down syndrome, as well as other individuals who may be facing the same medical issues.\6\ --------------------------------------------------------------------------- \1\INCLUDE Project | National Institutes of Health (NIH). \2\National Down Syndrome Society, Facts About Down Syndrome (2022), https://ndss.org/sites/default/files/2022-08/2022 Down Syndrome Fact Sheet.pdf. \3\Id. \4\National Institute on Aging (NIA), Alzheimer's Disease in People with Down Syndrome (Nov. 30, 2020), https://www.nia.nih.gov/health/ alzheimers-causes-and-risk-factors/alzheimers-disease-people-down- syndrome. \5\Santoro & Bulova., Common Health Conditions in Adults with Down Syndrome (Oct. 2025), National Down Syndrome Society, https:// careds.org/wp-content/uploads/Common-Health- Conditions_Reference-Article.pdf. \6\NIA, supra note 3. ---------------------------------------------------------------------------

Committee Action

On February 14, 2024, the Subcommittee on Health held a hearing on H.R. 3491. The title of the hearing was ``Legislative Proposals to Support Patients and Caregivers.'' The Subcommittee received testimony from: Dr. Andy Shih, PhD, Chief Science Officer, Autism Speaks; Mr. Corey Feist, JD, MBA, Co-Founder and CEO, Dr. Lorna Breen Heroes' Foundation; Dr. Joanne Pike, DrPH, President and CEO, Alzheimer's Association; Dr. Gordon Tomaselli, MD, Former President, American Heart Association; Marilyn and Stanley M. Katz Dean, Emeritus and Professor of Medicine, Albert Einstein College of Medicine; Adjunct Professor of Medicine, Johns Hopkins University School of Medicine; Ms. Michelle Whitten, President, CEO, and Co-Founder, Global Down Syndrome Foundation; Mr. Randy Strozyk, President, American Ambulance Association; and, Dr. Christina Annunziata, MD, PhD, Senior Vice President of Extramural Discovery Science, American Cancer Society. On March 12, 2024, the Subcommittee on Health met in open markup session and forwarded H.R. 7406, as amended, to the full Committee by a voice vote. On March 20, 2024, the full Committee on Energy and Commerce met in open markup session and ordered H.R. 7406, as amended, favorably reported to the House by a record vote of 45 yeas and 0 nays. On May 21, 2026, the full Committee on Energy and Commerce met in open markup session and ordered H.R. 3491, without amendment, favorably reported to the House by a record vote of 46 yeas and 0 nays.

Committee Votes

Clause 3(b) of rule XIII requires the Committee to list the record votes on the motion to report legislation and amendments thereto. The following reflects the record votes taken during the Committee consideration: Oversight Findings and Recommendations Pursuant to clause 2(b)(1) of rule X and clause 3(c)(1) of rule XIII, the Committee held a hearing and made findings that are reflected in this report. New Budget Authority, Entitlement Authority, and Tax Expenditures Pursuant to clause 3(c)(2) of rule XIII, the Committee finds that H.R. 3491 would result in no new or increased budget authority, entitlement authority, or tax expenditures or revenues.

Congressional Budget Office Estimate

Pursuant to clause 3(c)(3) of rule XIII, at the time this report was filed, the cost estimate prepared by the Director of the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974 was not available. Federal Mandates Statement The Committee adopts as its own the estimate of Federal mandates prepared by the Director of the Congressional Budget Office pursuant to section 423 of the Unfunded Mandates Reform Act. Statement of General Performance Goals and Objectives Pursuant to clause 3(c)(4) of rule XIII, the general performance goal or objective of this legislation is to promote the scientific understanding of Down syndrome and co-occurring conditions. Duplication of Federal Programs Pursuant to clause 3(c)(5) of rule XIII, no provision of H.R. 3491 is known to be duplicative of another Federal program, including any program that was included in a report to Congress pursuant to section 21 of Public Law 111-139 or the most recent Catalog of Federal Domestic Assistance. Related Committee and Subcommittee Hearings Pursuant to clause 3(c)(6) of rule XIII, the following related hearing was used to develop or consider H.R. 3491: On February 14, 2024, the Subcommittee on Health held a legislative hearing on H.R. 7268. The title of the hearing was ``Legislative Proposals to Support Patients and Caregivers.'' The Subcommittee received testimony from: Dr. Andy Shih, PhD, Chief Science Officer, Autism Speaks; Mr. Corey Feist, JD, MBA, Co- Founder and CEO, Dr. Lorna Breen Heroes' Foundation; Dr. Joanne Pike, DrPH, President and CEO, Alzheimer's Association; Dr. Gordon Tomaselli, MD, Former President, American Heart Association; Marilyn and Stanley M. Katz Dean, Emeritus and Professor of Medicine, Albert Einstein College of Medicine; Adjunct Professor of Medicine, Johns Hopkins University School of Medicine; Ms. Michelle Whitten, President, CEO, and Co-Founder, Global Down Syndrome Foundation; Mr. Randy Strozyk, President, American Ambulance Association; and, Dr. Christina Annunziata, MD, PhD, Senior Vice President of Extramural Discovery Science, American Cancer Society. Committee Cost Estimate Pursuant to clause 3(d)(1) of rule XIII, the Committee adopts as its own the cost estimate prepared by the Director of the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974. At the time this report was filed, the estimate was not available. Earmark, Limited Tax Benefits, and Limited Tariff Benefits Pursuant to clause 9(e), 9(f), and 9(g) of rule XXI, the Committee finds that H.R. 3491 contains no earmarks, limited tax benefits, or limited tariff benefits. Advisory Committee Statement No advisory committees within the meaning of section 5(b) of the Federal Advisory Committee Act were created by this legislation. Applicability to Legislative Branch The Committee finds that the legislation does not relate to the terms and conditions of employment or access to public services or accommodations within the meaning of section 102(b)(3) of the Congressional Accountability Act. Section-by-Section Analysis of the Legislation Section 1. Short title Section 1 provides a short title of ``DeOndra Dixon INCLUDE Project Act of 2025.'' Section 2. DeOndra Dixon INCLUDE Project Section 2 directs the Secretary of the Department of Health and Human Services, acting through the Director of the National Institutes of Health, to establish and oversee the implementation of a research program focused on Down syndrome. This section also specifies certain program components that should be investigated and included within the research program, as well as implements Congressional reporting requirements. Changes in Existing Law Made by the Bill, as Reported In compliance with clause 3(e) of rule XIII of the Rules of the House of Representatives, changes in existing law made by the bill, as reported, are shown as follows (new matter is printed in italics and existing law in which no change is proposed is shown in roman): PUBLIC HEALTH SERVICE ACT * * * * * * * TITLE IV--NATIONAL RESEARCH INSTITUTES * * * * * * * Part B--General Provisions Respecting National Research Institutes * * * * * * * SEC. 409K. DOWN SYNDROME RESEARCH. (a) In General.--The Director of NIH shall carry out a program of research, training, and investigation related to Down syndrome to be known as the ``INvestigation of Co- occurring conditions across the Lifespan to Understand Down syndromE Project'' or the ``INCLUDE Project''. (b) Program Elements.--The program under subsection (a) shall include-- (1) high-risk, high-reward research on the effects of trisomy 21 on human development and health; (2) promoting research for participants with Down syndrome across the lifespan, including cohort studies to facilitate improved understanding of Down syndrome and co-occurring conditions and development of new interventions; (3) expanding the number of clinical trials that are inclusive of, or expressly for, participants with Down syndrome, including novel biomedical and pharmacological interventions and other therapies designed to promote or enhance activities of daily living; (4) research on the biological mechanisms in individuals with Down syndrome pertaining to structural, functional, and behavioral anomalies and dysfunction as well as stunted growth; (5) supporting research to improve diagnosis and treatment of conditions co-occurring with Down syndrome, including the identification of biomarkers related to risk factors, diagnosis, and clinical research and therapeutics; (6) research on the causes of increased prevalence, and concurrent treatment, of co-occurring conditions, such as Alzheimer's disease and related dementias and autoimmunity, in individuals with Down syndrome; and (7) research, training, and investigation on improving the quality of life of individuals with Down syndrome and their families. (c) Coordination; Prioritizing Nonduplicative Research.--The Director of NIH shall ensure that-- (1) the programs and activities of the institutes and centers of the National Institutes of Health relating to Down syndrome and co-occurring conditions are coordinated, including through the Office of the Director of NIH and priority-setting reviews conducted pursuant to section 402(b)(3); and (2) such institutes and centers, prioritize, as appropriate, Down syndrome research that does not duplicate existing research activities of the National Institutes of Health. (d) Consultation With Stakeholders.--In carrying out activities under this section, the Director of NIH shall, as appropriate and to the maximum extent feasible, consult with relevant stakeholders, including patient advocates, to ensure that such activities take into consideration the needs of individuals with Down syndrome. (e) Biennial Reports to Congress.-- (1) In general.--The Director of NIH shall submit, on a biennial basis, to the Committee on Energy and Commerce and the Subcommittee on Labor, Health and Human Services, Education, and Related Agencies of the Committee on Appropriations of the House of Representatives and the Committee on Health, Education, Labor, and Pensions and the Subcommittee on Labor, Health and Human Services, Education, and Related Agencies of the Committee on Appropriations of the Senate, a report that catalogs the research conducted or supported under this section. (2) Contents.--Each report under paragraph (1) shall include-- (A) identification of the institute or center involved; (B) a statement of whether the research is or was being carried out directly by such institute or center or by multiple institutes and centers; and (C) identification of any resulting real- world evidence that is or may be used for clinical research and medical care for patients with Down syndrome. * * * * * * * [all]

Source: https://api.congress.gov/v3/committee-report/119/hrpt/722